AI-Powered Nanopore Analysis for Next-Generation Protein Diagnostics

Breakthrough technology combines nanopore sensing with deep learning for precise identification of 42+ proteins simultaneously - a 4X improvement over conventional methods with potential for revolutionary point-of-care diagnostics.

• 42+ proteins classifiable (vs. 10 with conventional methods)
• 74.5-78.95% classification accuracy
• Real-time processing instead of hours-to-days analysis
• Standard FPGA hardware instead of specialized equipment
• Offline operation capability
• Scalability to thousands of protein types
• Minimal sample preparation
• Modular architecture for rapid adaptation to specific diagnostic panels

Clinical Diagnostics: Early disease detection, treatment monitoring, companion diagnostics, cancer biomarker detection, cardiac marker analysis. Pharmaceutical Research: Drug discovery, biomarker identification, clinical trials. Point-of-Care Diagnostics: Emergency medicine, primary care practices, decentralized laboratories. Personalized Medicine: Patient stratification, treatment optimization, precision therapeutics. Research Applications: Academic research, proteome mapping, systems biology.

The proteomics industry faces critical challenges in rapid and precise protein identification. The global proteomics market is estimated at USD 15.8 billion by 2028 and urgently seeks technologies that can accelerate drug discovery, enable early disease detection, and advance personalized medicine. Existing methods like mass spectrometry require extensive sample preparation and specialized equipment, while current nanopore approaches are limited to a maximum of 10 proteins.

Current proteomics methods suffer from fundamental limitations: Traditional mass spectrometry is unsuitable for point-of-care applications, while existing nanopore-based approaches can only classify 10 proteins due to overlapping signal characteristics. These restrictions prevent practical deployment in clinical settings where 42+ proteins are required for comprehensive diagnostic panels. The medical diagnostics market needs technologies capable of real-time multi-protein analysis with minimal sample preparation.

The patented technology revolutionizes protein identification through an innovative three-stage process: (1) Proteins traverse nanopores generating unique electrical signatures, (2) Wavelet transformation converts complex time-series signals into 2D image representations, (3) optimized CNN architectures (ResNet18/ResNext101) classify protein types with unprecedented accuracy. The breakthrough lies in transforming protein translocation signals into image space, making powerful computer vision algorithms accessible.